Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
NCT ID: NCT00163137
Last Updated: 2011-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
540 participants
INTERVENTIONAL
2003-05-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
NCT00046137
Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)
NCT00431431
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
NCT00674453
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
NCT00389740
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy
NCT00371956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lasofoxifene 0.25 mg
lasofoxifene 0.25 mg/day
lasofoxifene
lasofoxifene 0.25mg
raloxifene
raloxifene 60 mg/day
raloxifene
raloxifene 60 mg/day
Placebo
Placebo
Placebo
0 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lasofoxifene
lasofoxifene 0.25mg
raloxifene
raloxifene 60 mg/day
Placebo
0 mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any use of selective estrogen receptor modulators, investigational drugs, or recent use of osteoporosis treatments, certain hormones, or medication for blood clots or seizures.
48 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ligand Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ligand Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Albany, California, United States
Pfizer Investigational Site
Berkeley, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Oakland, California, United States
Pfizer Investigational Site
Oakland, California, United States
Pfizer Investigational Site
Palo Alto, California, United States
Pfizer Investigational Site
Poway, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Newark, Delaware, United States
Pfizer Investigational Site
Brandon, Florida, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Key Largo, Florida, United States
Pfizer Investigational Site
Lake Worth, Florida, United States
Pfizer Investigational Site
Leesburg, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Portland, Maine, United States
Pfizer Investigational Site
Bethesda, Maryland, United States
Pfizer Investigational Site
Gaithersberg, Maryland, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Southfield, Michigan, United States
Pfizer Investigational Site
Arden Hills, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Akron, Ohio, United States
Pfizer Investigational Site
Akron, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Monessen, Pennsylvania, United States
Pfizer Investigational Site
Mosessen, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
West Reading, Pennsylvania, United States
Pfizer Investigational Site
Wyomissing, Pennsylvania, United States
Pfizer Investigational Site
Wyomissing, Pennsylvania, United States
Pfizer Investigational Site
Chattanooga, Tennessee, United States
Pfizer Investigational Site
Chattanooga, Tennessee, United States
Pfizer Investigational Site
Cordova, Tennessee, United States
Pfizer Investigational Site
Germantown, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
American Fork, Utah, United States
Pfizer Investigational Site
Pleasant Grove, Utah, United States
Pfizer Investigational Site
Provo, Utah, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
West Jordan, Utah, United States
Pfizer Investigational Site
Chesapeake, Virginia, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2181030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.